Clinical Research
News & Careers
Search the Site
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login           Employers:  Register | Login   
 Top Breaking News
 Sunday, March 29, 2015

 Yesterday's Most Popular News 
Amgen (AMGN)'s deCODE genetics (DCGN) Publishes Largest Human Genome Population Study

Conatus Pharma Shares Soar On Successful Emricasan Phase II Results

Sushi Parasite Inspires Worm Test For Cancer, Kyushu University Study

Looking For Happiness In All The Wrong Places, Baylor University Study

New Research Throws Cold Water on Biogen (BIIB)'s Recent Breakthrough

Why Drug For Type II Diabetes Makes People Fat, Georgia State University Study

Merck & Co. (MRK) Study Halted on Positive Phase III Data

Just Slip Out The Back, Jack: Are Humans Hardwired To Break-Up And Move On? Saint Louis University Medical Center Study

Aridis Pharmaceuticals Commences Phase 1 Clinical Study Of Aerucin Monoclonal Antibody For Acute Pneumonia

Child With Autism Improves With Antibiotic, Microbial Ecology In Health And Disease Reveals


 Featured Stories
Crossing Fingers Can Reduce Feelings Of Pain, University College London Study
Fitness Level Associated With Lower Risk Of Some Cancers, Death In Men, University of Vermont Study
Widows May Have Fewer Social And Financial Problems Than In The Past, University of Bern Study
High-Fat Diet Alters Behavior And Produces Signs Of Brain Inflammation, Louisiana State University Study
Roseroot Herb Shows Promise As Potential Depression Treatment Option, University of Pennsylvania Team Finds
A Single Gene May Decide Why Some People Get So Sick With The Flu, Rockefeller University Study
Boston University/BMC Study Finds The Role Of Genes Is Greater With Living To Older Ages
Most Antibiotics During Pregnancy Are Unlikely To Cause Neurological Damage To Fetuses, Great Ormond Street Hospital Study
More Featured Stories

  Today's Top Jobs

 Featured Employer
About Genzyme Genzyme is committed to discovering and delivering transformative therapies for patients with rare and special unmet medical needs, providing hope where there was none before. Genzyme has pioneered the development and delivery of transformative therapies for over 30 years. Founded in 1981 in Boston, Massachusetts, Genzyme evolved from a tiny start-up with just a handful of employees to one of the world's leading biotech companies. Acquired by Sanofi in 2011, Genzyme now benefits from the reach and resources of one of the world’s largest pharmaceutical companies, with a shared commitment to improving the lives of patients. Genzyme has long been known for our expertise in the class of rare genetic diseases known as lysosomal storage disorders (LSDs). LSDs remain the heart of our company today, but we have also expanded – through both in-house development and strategic acquisitions and partnerships – to other disease areas such as thyroid cancer and multiple sclerosis. Learn more at Follow our jobs on Twitter Follow us on LinkedIn About Sanofi Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets, and animal health. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Show me jobs for this employer

More Career Tips